ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
pi065509
|
91 |
19K |
6 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
91
|
19K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
pi065509
|
91 |
19K |
15 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
91
|
19K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
106 |
22K |
6 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
106
|
22K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
106 |
22K |
8 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
22K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
106 |
22K |
10 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
22K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
106 |
22K |
14 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
22K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
106 |
22K |
13 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
22K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
$1 party
|
|
pi065509
|
21 |
4.8K |
2 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
21
|
4.8K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notification of expiry of quoted options
|
|
pi065509
|
43 |
9.4K |
9 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
43
|
9.4K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
pi065509
|
132 |
33K |
13 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
132
|
33K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
pi065509
|
132 |
33K |
1 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
132
|
33K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
pi065509
|
132 |
33K |
8 |
18/09/23 |
18/09/23 |
ASX - By Stock
|
132
|
33K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
pi065509
|
132 |
33K |
5 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
132
|
33K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
9 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
380
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
13 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
380
|
85K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
pi065509
|
126 |
29K |
5 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
126
|
29K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
pi065509
|
132 |
33K |
5 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
132
|
33K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
pi065509
|
95 |
23K |
6 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
95
|
23K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
pi065509
|
95 |
23K |
10 |
04/09/23 |
04/09/23 |
ASX - By Stock
|
95
|
23K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
9 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
10 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
85K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
7 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
85K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
21 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
85K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
12 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
85K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
pi065509
|
28 |
5.2K |
9 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
28
|
5.2K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
5 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
85K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
pi065509
|
380 |
85K |
11 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
85K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
78 |
21K |
14 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
78
|
21K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
pi065509
|
140 |
32K |
4 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
140
|
32K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
pi065509
|
140 |
32K |
10 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
140
|
32K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
pi065509
|
140 |
32K |
12 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
140
|
32K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
pi065509
|
140 |
32K |
9 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
140
|
32K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
pi065509
|
140 |
32K |
10 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
140
|
32K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
3 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
85K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
6 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
396
|
85K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
3 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
396
|
85K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
4 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
396
|
85K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
4 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
396
|
85K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
pi065509
|
218 |
51K |
4 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
pi065509
|
218 |
51K |
8 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
3 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
396
|
85K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes 3rd Patient Cohort
|
|
pi065509
|
48 |
11K |
10 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
48
|
11K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
pi065509
|
165 |
35K |
4 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
165
|
35K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
pi065509
|
165 |
35K |
6 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
165
|
35K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
pi065509
|
200 |
43K |
2 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
200
|
43K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
pi065509
|
200 |
43K |
3 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
200
|
43K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
pi065509
|
287 |
79K |
12 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
287
|
79K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
pi065509
|
165 |
35K |
10 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
165
|
35K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
9 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
396
|
85K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
pi065509
|
396 |
85K |
6 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
396
|
85K
|
6
|
|